Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine A + interferon gamma
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of cyclosporine A, an immunosuppressive agent that inhibits T-cell activation by blocking the production of cytokines, and interferon gamma, a cytokine with immunomodulatory properties. This combination has been studied for various applications including augmentation of graft-versus-host disease following bone marrow transplantation and treatment of myeloid malignancies.
- Other names
- cyclosporin-A + interferon-gammaCsA + IFN-gamma
02
Targets
IFNGR1 (Interferon gamma receptor 1)CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on cyclosporine A + interferon gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine A + interferon gamma.